Anaplastic Thyroid Carcinoma, Version 2.2015.

Détails

ID Serval
serval:BIB_A3CD5AB458B5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Anaplastic Thyroid Carcinoma, Version 2.2015.
Périodique
Journal of the National Comprehensive Cancer Network
Auteur⸱e⸱s
Haddad R.I., Lydiatt W.M., Ball D.W., Busaidy N.L., Byrd D., Callender G., Dickson P., Duh Q.Y., Ehya H., Haymart M., Hoh C., Hunt J.P., Iagaru A., Kandeel F., Kopp P., Lamonica D.M., McCaffrey J.C., Moley J.F., Parks L., Raeburn C.D., Ridge J.A., Ringel M.D., Scheri R.P., Shah J.P., Smallridge R.C., Sturgeon C., Wang T.N., Wirth L.J., Hoffmann K.G., Hughes M.
ISSN
1540-1413 (Electronic)
ISSN-L
1540-1405
Statut éditorial
Publié
Date de publication
09/2015
Peer-reviewed
Oui
Volume
13
Numéro
9
Pages
1140-1150
Langue
anglais
Notes
Publication types: Journal Article ; Practice Guideline
Publication Status: ppublish
Résumé
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Mots-clé
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carboplatin/administration & dosage, Docetaxel, Doxorubicin/administration & dosage, Humans, Paclitaxel/administration & dosage, Radiotherapy, Intensity-Modulated, Taxoids/administration & dosage, Thyroid Carcinoma, Anaplastic/diagnosis, Thyroid Carcinoma, Anaplastic/secondary, Thyroid Carcinoma, Anaplastic/therapy, Thyroid Neoplasms/diagnosis, Thyroid Neoplasms/pathology, Thyroid Neoplasms/therapy, Thyroidectomy
Pubmed
Web of science
Open Access
Oui
Création de la notice
27/12/2020 15:00
Dernière modification de la notice
28/12/2020 7:26
Données d'usage